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DBackground: Our aim was to determine whether general left main coronary artery stenosis (LMS) and ostial
LMS pose additional risks after off-pump coronary artery bypass grafting (CABG) relative to non–left main
coronary artery stenosis.
Methods: From January 1, 2008, to December 31, 2009, 4366 patients underwent primary isolated off-pump
CABG at Beijing Anzhen Hospital. Disease was retrospectively classified as non–left main disease
(n ¼ 3523), nonostial LMS (n ¼ 765), and ostial LMS (n ¼ 78). Groups were propensity score matched.
Kaplan-Meier freedoms from major adverse cardiac and cerebrovascular events (MACCEs) were calculated.
Results: During the first 30 postoperative days, mortality was significantly higher in the ostial LMS group
(6.41%) than in non–left main disease (0.855%, c2 ¼ 7.78, P ¼ .005) and nonostial LMS (1.28%,
c2 ¼ 4.71, P ¼ .03) groups. Incidence of MACCEs was significantly higher in the ostial LMS group
(20.5%) than in non–left main disease (5.98%, P ¼ .000) and nonostial LMS (9.62%, P ¼ .002) groups.
Odds ratio for early MACCEs of ostial LMS versus non–left main disease was 3.74 (95% confidence interval,
1.72–8.17). At mean follow-up 12.8  7.5 months and cumulative follow-up 498.5 patient-years, difference
among groups in freedom from MACCEs did not reach statistical significance (c2 ¼ 2.39, P ¼ .303).
Conclusions:Ostial LMS poses additional early risks of mortality and MACCEs in off-pump CABG. Off-pump
CABG for ostial LMS should proceed with greater of intraoperative surveillance and lower threshold for
converting to on-pump CABG. (J Thorac Cardiovasc Surg 2012;143:103-10)Because of improvements in the perioperative and postoper-
ative management of patients undergoing coronary artery
bypass grafting (CABG), left main coronary artery stenosis
(LMS) no longer is a risk factor for early and late death after
CABG.1 According to current guidelines, CABG remains
the treatment of choice for patients with severe coronary
artery disease, including those with LMS and those with
3-vessel disease.2,3 Even in this era of drug-eluting stent
therapy, CABG remains the standard of care for patients
with 3-vessel disease or LMS, because the use of CABG,
as compared with percutaneous coronary intervention
(PCI), has resulted in lower rates of the combined end point
of major adverse cardiac and cerebrovascular events
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The Journal of Thoracic and CaIn our high-volume practice of revascularization proce-
dures, we have believed that significant ostial LMS, al-
though a relatively rare entity, is associated with relatively
higher in-hospital and long-term mortalities after off-
pumpCABG (OPCAB).AlthoughOPCABhas now evolved
as routine practice in some cardiac centers, its relative safety
and efficacy in ostial LMS relative to coronary artery disease
other than LMS (non–left main disease) and to general
(nonostial) LMS has never been explored. In this study, we
therefore retrospectively evaluated the relative efficacy
and safety profiles of OPCAB for patients with non–left
main disease, nonostial LMS, and ostial LMS. To correct
for the confounding factors and to decrease the potential se-
lection bias, we used propensity scores to match 3 groups,
allowing direct comparisons of outcomes during the first
30 days after the procedure and during the midterm
follow-up.MATERIALS AND METHODS
Study Design
From January 1, 2008, through December 31, 2009, a total of 4742 pa-
tients underwent CABG at the Beijing Anzhen Hospital. Among these,
4366 (92.1%) with previously untreated coronary artery disease underwent
primary isolated OPCAB and 376 (7.9%) underwent on-pump CABG. Ac-
cording to the pathology of the left main coronary artery, the 4366 patients
who underwent OPCAB were retrospectively classified as having non–left
main disease (n¼ 3523), nonostial LMS (n¼ 765), or ostial LMS (n¼ 78).
The non–left main disease group was defined as the group of patients who
had coronary artery disease but did not have left main coronary arteryrdiovascular Surgery c Volume 143, Number 1 103
Abbreviations and Acronyms
CABG ¼ coronary artery bypass grafting
IABP ¼ intra-aortic balloon pump
LMS ¼ left main stenosis
MACCE ¼ major adverse cardiac and
cerebrovascular event
OPCAB ¼ off-pump coronary artery bypass
grafting
PCI ¼ percutaneous coronary intervention
SYNTAX ¼ Synergy Between Percutaneous
Coronary Intervention With TAXUS
and Cardiac Surgery
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Dstenosis. The nonostial LMS group was defined as the group of patients
who had left main coronary artery disease in addition to other coronary le-
sions but did not have ostial left main coronary artery stenosis. Finally, the
ostial LMS group was defined as the group of patients who had ostial LMS
in addition to other coronary lesions. The 376 patients who underwent
on-pump procedures, including primary on-pump CABG (n ¼ 52), con-
comitant valve replacement (n ¼ 233), left ventricular aneurysmectomy
(n ¼ 43), mitral valve repair (n ¼ 45), and tricuspid valve repair (n ¼ 3),
were excluded from this study. Patient ages ranged from 39 to 78 years
(mean 62.7  16.3 years). Overall, 1070 patients (24.5%) had Canadian
Cardiovascular Society angina class IV symptoms. LMS was defined as
at least 50% stenosis in the left main coronary artery, and ostial LMS
was defined as stenosis of the proximal left main coronary artery, less
than 3 mm from the ostium, of at least 50%. We calculated propensity
scores tomatch similar clinical characteristics among the 3 groups. Logistic
regression with backward selection was performed to calculate the propen-
sity score. By matching propensity score, 78 foursomes were successfully
matched in a manner of 3 members from the non–left main disease group
(n ¼ 78 3 3 ¼ 234) with 1 member from the ostial LMS group (n ¼ 78).
Moreover, 78 threesomeswere successfullymatched in amanner of 2mem-
bers from the nonostial LMS group (n¼ 783 2¼ 156)with 1member from
the ostial LMS group (n ¼ 78). We compared the clinical results among
these propensity-matched groups. In Table 1, which presents the preopera-
tive demographic characteristics and risk factors of the 3 groups after
matching, patients in the 3 groups can be seen to be well balanced with
regard to all the baseline demographic and clinical characteristics.
The local ethics committee at Anzhen Hospital and Beijing Institute of
Heart, Lung, and Blood Vessel Diseases approved the use of clinical data
for this study. Written, informed consent was obtained from each patient
for the surgical or interventional procedure, and consent was also obtained
from each patient for use of the data in clinical research.
Procedure Indication and Techniques
Six surgical teams affiliated with Anzhen Hospital performed all the
CABG procedures. In our center, off-pump CABG had been performed
regularly for more than 10 years before the launch of the trial, and each
of the 6 participating surgical teams have performed at least 85% of their
isolated CABG as off-pump procedures since 2005. The indications for
OPCAB in our hospital included all isolated CABG procedures with
a reasonable target vessel but without large left ventricular aneurysm,
severe mitral valve regurgitation, left ventricular thrombus, severe arrhyth-
mia originating from myocardial infarction, or severe comorbidities mak-
ing OPCAB impossible. Contraindications to OPCAB included inadequate
exposure and aberrant coronary arterial anatomy, such as poorly visualized
target vessels on angiography or extremely small, heavily calcified, or104 The Journal of Thoracic and Cardiovascular Surgextensively intramyocardial vessels. Preoperative hemodynamic instability
was also a contraindication to OPCAB. The indication for on-pump CABG
included all CABG procedures with poor target vessel, large left ventricu-
lar aneurysm with a volume between 20% and 50% of the left ventricle,
severe mitral valve regurgitation, left ventricular thrombus, or severe co-
morbidities necessitating cardiopulmonary bypass. Large left ventricular
aneurysm was defined as a dyskinetic left ventricular wall with a volume
greater than 20% of the left ventricle, as assessed through left ventriculog-
raphy and echocardiography. Severe mitral valve regurgitation was defined
as a regurgitation area greater than 9 cm2, as assessed through left ventri-
culography and either transthoracic or transesophageal echocardiography.
The strategy for all isolated CABG procedures in Anzhen Hospital was
regularly planned first to proceed as an OPCAB procedure; if the hemody-
namic situation was unstable or could not sustain the off-pump manipula-
tion, however, the surgery would be switched to on-pump CABG. All the
OPCAB procedures were performed through a median sternotomy ap-
proach under conditions of general anesthesia. We used electrocardiogra-
phy and blood pressure measured through a radial artery catheter to
monitor hemodynamic status. In patients with a left ventricular ejection
fraction value less than 35%, a Swan-Ganz catheter was also used to mon-
itor continuous cardiac output. There were always bypass setups available
in the operating room. All patients were given heparin at 100 IU/kg intra-
venously to achieve an activated clotting time longer than 300 seconds. An
Octopus stabilizer (Medtronic, Inc, Minneapolis, Minn) was used for the
distal anastomosis, and a Novare Enclose II manual proximal anastomotic
device (Vitalitec International, Inc Plymouth, Mass) was used for the prox-
imal anastomosis. The distal anastomoses were constructed with a continu-
ous running 7-0 polypropylene suture, and the proximal venous or arterial
graft anastomosis to the aorta was sutured over a partially secluded area in
aortawith a continuous running 6-0 polypropylene suture bymeans of aNo-
vare Enclose II manual proximal anastomotic device. All patients in the 3
groups were advised to continue lifelong aspirin therapy (100 mg daily).
Study End Points
The primary end point was all-cause mortality within 30 days after the
revascularization procedure and during the follow-up. The secondary end
point was the incidence of MACCEs within 30 days after the revasculari-
zation procedure and during the follow-up. MACCEs were defined to
include all-cause death, nonfatal myocardial infarction, stroke, and re-
peated revascularization. Repeated revascularization was defined as any
PCI or CABG performed after the first revascularization procedure.
Non–Q-wave myocardial infarction was diagnosed according to World
Health Organization criteria, including an increase in total creatine kinase
level to at least twice the upper limit of the reference range and an elevated
MB isoform level without development of new pathologic Q waves.
A Q-wave myocardial infarction was present when, in addition to creatine
kinase elevation, a new pathologic Q wave was noted in at least 2 of the
electrocardiographic leads.
Data Collection
Among the 468 cases from the 3 propensity-matched groups, there were
460 surgical survivors. One month after discharge, all these surviving
patients were assessed at an outpatient clinic for full review by the cardiac
surgeon or cardiologist. Canadian Cardiovascular Society angina class,
troponin I and cardiac enzymes, transthoracic echocardiography, and
electrocardiographic data were recorded. These variables were evaluated
at 3-month intervals at the patient’s local cardiac center. Long-term clini-
cal outcomes were assessed up to July 2010 by reviewing the medical files
of patients’ cardiologists, general practitioners, or both as appropriate.
Baseline demographic data, procedural data, and perioperative outcomes
were recorded. For deaths beyond the first 30 days after the CABG proce-
dure, the medical files were reviewed by a primary investigator (H-L.G.,
C-S.L., or P-S. W) of this study. The status of the patients was determined
by review of hospital records, follow-up questionnaires, or contact withery c January 2012
TABLE 1. Preoperative baseline demographic variables and risk factors in the group with other than left main disease, the group with nonostial
left main stenosis, and the group with ostial left main stenosis after matching
Patient data
Non–left main
disease (n ¼ 234)
Nonostial
LMS (n ¼ 156)
Ostial
LMS (n ¼ 78) P value F or c2
Age (y, mean  SD) 59.45  11.43 58.56  10.33 58.30  11.13 .623 0.47
Age>65 y (no.) 96 66 32 .966 0.07
SYNTAX score (mean  SD) 28.6  12.4 28.9  11.5 29.7  11.1 .789 0.25
EuroSCORE (mean  SD) 6.2  2.6 6.4  2.8 6.5  2.7 .620 0.478
Female (no.) 99 62 30 .791 0.47
All types of diabetes mellitus (no.) 117 74 38 .884 0.25
Type 1 diabetes mellitus (no.) 39 24 10 .718 0.67
HSCRP (mg/L, mean  SD) 4.53  2.06 4.46  2.17 4.35  2.14 .803 0.22
Hyperlipidemia (no.) 177 106 57 .247 2.80
Current smoker (no.) 120 80 38 .918 0.17
Renal insufficiency (no.) 21 12 5 .751 0.57
Hypertension (no.) 162 106 51 .817 0.40
Family history of coronary artery disease (no.) 90 60 31 .978 0.05
Previous MI (no.) 114 78 40 .053 5.90
Peripheral vascular disease (no.) 18 12 5 .172 3.52
LV ejection fraction<35% (no.) 30 18 9 .914 0.18
LV ejection fraction (%, mean  SD) 53.5  16.4 54.3  17.6 55.2  16.7 .724 0.32
Congestive heart failure (no.) 36 22 10 .842 0.34
Transient ischemic attack (no.) 12 8 3 .892 0.23
Stroke (no.) 9 6 3 .923 0.16
Pulmonary disease (no.) 24 14 6 .778 0.50
CCS angina class IV (no.) 91 62 35 .164 3.61
Periprocedural IABP (no.) 5 4 2 .955 0.09
Aspirin (no.) 234 156 78 >.999 0
b-Blocker (no.) 201 132 64 .711 0.68
Calcium-channel blocker (no.) 108 70 33 .838 0.35
Nitrates (no.) 210 142 72 .778 0.50
Statins (no.) 144 102 50 .732 0.63
Electrocardiographic diagnosis (no.) .875 1.22
Sinus rhythm 213 144 73
Atrial fibrillation 15 10 4
Other rhythm 6 2 1
Enrollment diagnosis (no.) .967 1.39
Silent ischemia 12 6 3
Stable angina* 51 30 14
Unstable anginay 153 106 54
Acute MI 18 14 7
Vessel territory with stenosis (no.)
RCA 187 124 63 .974 0.05
Total RCA occlusion 17 12 6 .985 0.03
90% Proximal RCA lesion 29 21 10 .953 0.10
LAD 234 156 78 >.999 0
LCX 234 156 78 >.999 0
Small LV aneurysmz (no.) 27 14 8 .719 0.66
LMS, Left main stenosis; HSCRP, high-sensitivity C-reactive protein; MI, myocardial infarction; LV, left ventricular; CCS, Canadian Cardiovascular Society; IABP, intra-aortic
balloon pump; RCA, right coronary artery; LAD, left anterior descending coronary artery; LCX, left circumflex coronary artery. *Stable angina was defined according to the
Canadian Cardiovascular Society system. yUnstable angina was classified according to the Braunwald classification. zSmall left ventricular aneurysm was defined as left
ventricular aneurysm with a volume less than 20% of the left ventricle.
Gan et al Acquired Cardiovascular Disease
A
C
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Detailed information, including Canadian Cardiovascular Society angina
class status, cardiac rhythm, complications and present medications
were recorded. At the follow-up, transthoracic echocardiography and elec-
trocardiography were assessed in 458 of the 460 patients surviving hospi-
talization (99.57%), and the main parameters were collected. PatientThe Journal of Thoracic and Cademographic data, preoperative risk factors, and the incidences of adverse
postoperative outcomes were retrieved from the Digitalcare database at
Beijing Anzhen Hospital. Diagnostic angiograms were scored according
to the Synergy Between Percutaneous Coronary InterventionWith TAXUS
and Cardiac Surgery (SYNTAX) score5 and EuroSCORE algorithms by 1
investigator (H-L.G., C-S.L., or P-S. W) of this study.rdiovascular Surgery c Volume 143, Number 1 105
TABLE 2. Clinical end points within first 30 days after the revascularization and during follow-up for the propensity score–matched cohorts
Non–left
main disease
Nonostial
LMS
Ostial
LMS
Nonostial LMS vs non–left main disease Ostial LMS vs non–left main disease
OR 95% CI P value c2 OR 95% CI P value c2
First 30 days
No. of patients 234 156 78
Death 2 (0.86%) 2 (1.28%) 5 (6.41%) 1.51 0.21–10.81 0.682 0.17 7.95 1.51–41.82 0.004 8.23
MI 6 (2.56%) 6 (3.85%) 5 (6.41%) 1.52 0.48–4.80 0.473 0.52 2.60 0.77–8.78 0.111 2.54
Stroke 4 (1.71%) 3 (1.92%) 3 (3.84%) 1.13 0.25–5.11 0.877 0.02 2.30 0.50–10.51 0.270 1.22
Death, MI, or stroke 12 (5.13%) 11 (7.05%) 13 (16.7%) 1.40 0.61–3.27 0.430 0.62 3.36 1.44–7.84 0.001 10.57
Redo CABG* 1 (0.43%) 0 (0%) 1 (1.28%) 0.29 0.002–41.52 0.415 0.66 3.03 0.19–48.96 0.413 0.67
Redo PCIy 1 (0.43%) 2 (1.28%) 2 (2.56%) 3.03 0.27–33.66 0.344 0.90 6.13 0.55–168.57 0.094 2.81
Repeat revascularizationz 2 (0.86%) 2 (1.28%) 3 (3.85%) 1.51 0.21–10.81 0.682 0.17 4.64 0.76–28.30 0.068 3.32
Any MACCEs 14 (5.98%) 15 (9.62%) 16 (20.5%) 1.67 0.78–3.57 0.180 1.79 3.74 1.72–8.17 0.000 13.88
Midterm follow-up
No. of patients 232 154 73
Death 2 (0.86%) 2 (1.30%) 1 (1.37%) 1.51 0.21–10.86 0.678 0.17 1.58 0.14–17.63 0.710 0.14
MI 6 (2.59%) 5 (3.25%) 4 (5.5%) 1.26 0.38–4.22 0.702 0.15 2.15 0.59–17.85 0.235 1.41
Stroke 8 (3.45%) 5 (3.25%) 3 (4.1%) 0.94 0.30–2.92 0.219 1.51 1.18 0.301–4.58 0.808 0.06
Death, MI, or stroke 16 (6.90%) 12 (7.79%) 8 (10.9%) 1.14 0.52–2.48 0.740 0.11 1.64 0.67–3.99 0.276 1.19
Redo CABG* 0 (0%) 0 (0%) 0 (0%) NA >.999 NA >.999
Redo PCIy 2 (0.86%) 2 (1.30%) 3 (4.1%) 1.513 0.21–10.86 0.678 0.17 4.86 0.80–29.67 0.059 3.557
Repeat revascularizationz 2 (0.86%) 2 (1.30%) 3 (4.1%) 1.513 0.21–10.86 0.678 0.17 4.86 0.80–29.66 0.059 3.557
Any MACCEs 18 (7.76%) 14 (9.09%) 11 (15.1%) 1.89 0.57–2.47 0.689 0.16 2.08 0.93–4.62 0.069 3.303
LMS, Left main stenosis; OR, odds ratio; CI, confidence interval; MI, myocardial infarction; CABG, coronary artery bypass grafting; PCI, percutaneous coronary intervention;
MACCEs, major adverse cardiac and cerebrovascular events; NA, not applicable. *Any coronary artery bypass grafting after the index coronary artery bypass grafting. yAny
percutaneous coronary intervention after the index coronary artery bypass grafting. zAny coronary artery bypass grafting or percutaneous coronary intervention after the index
coronary artery bypass grafting.
Acquired Cardiovascular Disease Gan et al
A
C
DStatistical Analysis
All statistical analyses were performed with the statistical software
package SPSS 17.0 (SPSS Inc, an IBM Company, Chicago, Ill). Categoric
data are summarized as frequencies and percentages. Continuous data are
given as mean SD. Cumulative event rates, such as freedom fromMAC-
CEs, of the 3 groups were estimated bymeans of the Kaplan-Meier method.
Differences among patients in the 3 groups were analyzed with 1-way
analysis of variance, interactive c2 test,6 Fisher’s Exact test, Wilcoxon
rank sum test, or log-rank test as appropriate.RESULTS
Revascularization Data
The results reported here focus on the 3 propensity-
matched groups. The average interval between the diagnos-
tic angiogram and the CABG procedure was 4.5 3.7 days.
Because of the unstable hemodynamic situation during the
intended off-pump manipulation, there were 5 (2.14%), 3
(1.92%), and 8 (10.26%) conversions to on-pump CABG
in the non–left main disease group, the nonostial LMS
group, and the ostial LMS group, respectively. The rate of
conversion to cardiopulmonary bypass in the ostial LMS
group was statistically significantly higher than the rates
in the non–left main disease group (c2 ¼ 9.66, P ¼ .002)
and the nonostial LMS group (c2 ¼ 8.06, P ¼ .004). Of
the 8 patients with conversion in the ostial LMS group, all
had greater than 90% stenosis at the ostial site of the left
main coronary artery, whereas of the 70 patients without
conversion, only 12 had greater than 90% stenosis at the106 The Journal of Thoracic and Cardiovascular Surgostial site of the left main coronary artery (Fisher’s Exact
test, P<.001).
All patients in the 3 groups used the left internal thoracic
artery as a bypass conduit. A second artery conduit, such
as the right internal thoracic artery or the radial artery,
was also used in the non–left main disease group in 21 pa-
tients (7.98%), the nonostial LMS group in 11 patients
(7.06%), and the ostial LMS group in 5 patients (6.41%).
The difference in multiple arterial conduit use among the
3 groups did not reach statistical significance (c2
P ¼ .237, P ¼ .346). There were 5 (2.14%), 4 (2.56%),
and 3 (3.85%) patients in the non–left main disease group,
the nonostial LMS group, and the ostial LMS group, respec-
tively, who received intra-aortic balloon pump (IABP)
support during the perioperative period. The difference in
the rate of IABP use among the 3 groups did not reach
statistical significance (c2 ¼ 0.684, P ¼ .710).Outcomes During the First 30 Days
As presented in Table 2, the mortality during the first 30
days in the ostial LMS group (6.41%) was significantly
higher than the mortalities in the non–left main disease
group (0.855%, c2 ¼ 7.78, P ¼ .005) and the nonostial-
LMS group (1.28%, c2 ¼ 4.71, P ¼ .03). The odds ratio
for ostial LMS versus non–left main disease was 7.95
(95% confidence interval, 1.51–41.82; c2 ¼ 8.23;ery c January 2012
TABLE 3. The reasons for all deaths during the first 30 days and at
midterm after off-pump coronary artery bypass grafting procedure
in the ostial left main stenosis group
Postoperative interval Comments
During the first 30 days after off-pump CABG procedure
1 6 d Cardiac arrest during the procedure
and conversion to on-pumpCABG;
patient died of low-output
syndrome
2 9 d Tachycardiac arrhythmia and cardiac
arrest during the procedure and
conversion to on-pump CABG;
patient died of low-output
syndrome
3 12 d Cardiac arrest during the procedure
and conversion to on-pumpCABG;
patient died of low-output
syndrome and renal failure
4 17 d Tachycardiac arrhythmia and cardiac
arrest during the procedure and
conversion to on-pump CABG;
patient died of low-output
syndrome
5 21 d Acute myocardial infarction and
circulatory collapse
During midterm after off-pump CABG procedure
6 10 mo Sudden death from acute myocardial
infarction
CABG, Coronary artery bypass grafting.
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DP¼ .004). The reasons for the deaths during the first 30 days
and midterm after off-pump CABG in the ostial LMS group
are presented in Table 3. The rate of the composite end point
of death,myocardial infarction, and stroke during the first 30
days in the ostial LMS group (15.39%) was significantly
higher than the rates in the non–left main disease group
(5.13%) and the nonostial LMS group (7.05%,
c2¼ 8.955, P¼ .011). The odds ratio for ostial LMS versus
non–left main disease was 3.364 (95% confidence interval
1.443–7.839). The rate of MACCEs during the first 30
days in the ostial LMS group (19.23%) was significantly
higher than the rates in the non–left main disease group
(5.98%) and the nonostial LMS group (9.62%,
c2¼ 12.066,P¼ .002). The odds ratio for ostial LMSversus
non–left main disease was 3.742 (95% confidence interval,
1.715–8.165).Midterm Clinical Follow-up
Of the 460 survivors from the 3 propensity-matched
groups, 3 were unavailable for follow-up. Follow-up was
complete for 99.35%. The mean follow-up was (12.8 
7.5 months, with a range of 1 to 26 months, and the
cumulative follow-up was 498.5 patient-years. As presented
in Table 2, the difference in the incidence of MACCEsThe Journal of Thoracic and Caduring follow-up among the ostial LMS group (13.51%),
the non–left main disease group (7.76%), and the nonostial
LMS group (9.09%) did not reach statistical significance
(c2 ¼ 3.361, P ¼ .186). The difference in the freedom
from MACCEs among the 3 groups, calculated through
the Kaplan-Meier method, also did not reach statistical sig-
nificance (c2 ¼ 2.39, P ¼ .303; Table 4 and Figure 1).
DISCUSSION
LMS is an important independent risk factor for in-
creased mortality and morbidity at all stages of diagnosis
and treatment of coronary artery disease. Although there
have been advances in the percutaneous treatment of
LMS, resulting in indications for PCI in clearly defined pa-
tient groups with LMS, CABG still confers a significant
event-free survival benefit relative to percutaneous and
medical treatment in both high- and low-risk patient sub-
sets.7,8 Thus, as implemented in the commonly accepted
guidelines of the American Heart Association (with
a level of evidence of A), CABG remains the treatment of
choice for patients with LMS.9 Even in the era of drug-
eluting stent therapy, CABG generally remains the method
of choice for patients with LMS.5-7
Until recently, the presence of critical LMS was consid-
ered a relative contraindication to the use of off-pump tech-
niques. Such inferences, however, were based on data
presented in the 1970s to the first half of this decade,
when the techniques of surgery, anesthesia, and medical
management were less advanced than they are now. During
recent years, there have been major improvements in almost
all fields relating to the perioperative management of pa-
tients undergoing CABG as a result of better management,
with options including more frequent use of arterial grafts,
greater use of internal thoracic arteries, and improved
techniques in off-pump surgery. Especially, hemodynamic
disturbances during displacement of the heart have been
minimized, thanks to improvements in stabilizer technol-
ogy, use of intracoronary shunts, and greater surgical and,
perhaps most importantly, anesthetic experience.
OPCAB technique was among the major areas of prog-
ress in coronary revascularization, and it has evolved as
a regular practice in some cardiac centers. For example,
in our cardiac center, we do about 2500 isolated CABG
procedures yearly, and more than 85% of the isolated
CABG procedures since 2005 in our cardiac center have
been completed in off-pump manner. There is a large
amount of evidence to prove the safety and efficacy of OP-
CAB for LMS now. Beauford and colleagues10 proved that
multivessel off-pump revascularization in patients with se-
vere LMS is a safe and effective alternative to conventional
CABG and conveys a survival benefit. Yeatman and associ-
ates11 also demonstrated that OPCAB is safe and effective
in patients with critical LMS in terms of early and late mor-
tality and MACCEs. Suzuki and colleagues12 have alsordiovascular Surgery c Volume 143, Number 1 107
TABLE 4. Freedoms frommajor adverse cardiac and cerebrovascular
events for groups with other than left main disease, nonostial left main
stenosis, and ostial left main stenosis after propensity score correction
Non–left main disease Nonostial LMS Ostial LMS
12 mo 93.9%  1.8% 94.2%  2.2% 89.9%  3.9%
18 mo 90.9%  2.5% 91.0%  3.1% 84.3%  5.4%
24 mo 89.5%  2.8% 78.8%  6.4% 74.4%  8.2%
Log-rank test for Kaplan-Meier major adverse cardiac and cerebrovascular event–
free curve among non–left main disease, nonostial left main stenosis, and ostial left
main stenosis groups, c2 ¼ 2.39, P ¼ .303 (the P value and c2 both refer to overall
comparison). LMS, Left main stenosis.
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all patients, without the need for exclusion criteria. Early
and midterm outcomes were acceptable and encouraged
continued use of the OPCAB approach for all patients
undergoing CABG, including critical LMS. Karic and col-
leagues13 revealed that OPCAB is an effective and safe
method for treatment of LMS, and there are certain advan-
tages relative to the classic method in short-term follow-up,
with no difference in long-term results. Panesar and col-
leagues14 demonstrated that OPCAB could offer a neuro-
logic benefit for patients with significant LMS undergoing
CABG. Suzuki and colleagues15 reported that OPCAB is
also feasible and safe for patients with LMS and that
LMS, critical or otherwise, is not recognized as a risk factor
after OPCAB in either the short or the long term. Emmert
and colleagues16 also reported that a modern OPCAB ap-
proach offers low mortality, confers excellent clinical out-
comes, and does not come at the price of less complete
revascularization in these high-risk patients, such as those
with severe LMS. The ROOBY study17 concluded that at
1 year of follow-up patients in the off-pump group had
worse composite outcomes and poorer graft patency than
did patients in the on-pump group. In that study, however,
the difference in the 30-day composite end point between
the off-pump and on-pump groups did not reach statistical
significance (P¼ .19), and the difference in the 1-year com-
posite end point was only marginally significant (P ¼ .04).
This leaves too much room for uncertainty whether OPCAB
alone was accountable for the difference. Their conclusion
therefore seems unwarranted.
None of these studies, however, explored the effect of the
special left main coronary artery lesions, such as ostial
LMS, on the early and medium to long-term outcomes after
OPCAB procedure. This study was designed to compare the
early and midterm clinical outcomes of OPCAB among pa-
tients with non–left main disease, nonostial-LMS, and ostial
LMS after correction by propensity score. The results of
OPCAB in patients with nonostial LMS in our study were
comparable with those in other reports with respect to early
mortality18,19; however, the early mortality among patients
with ostial LMS was much higher than that among patients
with non–left main disease or nonostial LMS. Therefore, in108 The Journal of Thoracic and Cardiovascular Surgcontrast to nonostial LMS, ostial LMS poses additional risk
to OPCAB with respect to early mortality and MACCEs
after the correction by propensity score.
Two features of OPCAB could lead to hemodynamic in-
stability: transient occlusion of coronary arteries during dis-
tal anastomosis construction and displacement of the heart
to provide access to distal coronary arteries. It is generally
believed that bifurcation lesions carry a worse prognosis
than do ostial and midshaft lesions in patients with unpro-
tected LMS treated with PCI20; however, our retrospective
study found that for the OPCAB procedure, ostial LMS car-
ries a higher risk than both nonostial LMS and non–left
main disease. As all we know, the left main coronary artery
could be divided into 3 parts21; that is, the origin of the left
main coronary artery from just above the left sinus of
Valsalva (the ostium), a midportion (the body), and a distal
portion or bifurcation. The ostium has a greater proportion
of smooth muscle and elastic tissue than the rest of the cor-
onary vessels.22 The smooth muscle and elastic tissue in the
ostium of the left main coronary artery, which is always
hypertrophied in ostial LMS, is more sensitive to the heart
displacement during the procedure than is nonostial LMS.
This sensitivity always leads to the spasm of the ostial
LMS lesion. The spasms of the ostial LMS lesion during
the displacement maneuver often lead to severe ischemia
in the left coronary artery territory, and the resulting unsta-
ble hemodynamic status often leads to cardiac arrest and
emergency conversion to on-pump CABG. In our analysis,
a higher incidence of circulatory arrest, which in turn
resulted in higher incidence of conversion to on-pump
CABG, was the main reason for the higher early mortality
and incidence of MACCEs for ostial LMS. In this study, of
the 5 early deaths in the ostial LMS group, 4 deaths were re-
lated to a sudden circulatory arrest during the procedure and
then prompt conversion to on-pumpCABG, eventually lead-
ing to death (Table 3). The specific pathology in the ostial
LMS lesion may be the reason for the higher portion of con-
version to on-pump CABG for ostial LMS. We found that
within the ostial LMS group, the patients who had conver-
sion had a higher rate of severe stenosis (90%) in the ostial
site in the left main coronary artery than did patients not hav-
ing conversion. Therefore, 90% or greater stenosis might be
a marker that could inform the decision of whether to use an
IABP during OPCAB or just do it on pump.
We have found no previous reports attempting to corre-
late ostial LMS with the outcome after CABG. As a special
entity of aorto-ostial lesion, ostial LMS should be empha-
sized in the treatment of coronary artery disease, because
ostial LMS accounted for 9.25% of the 843 cases of LMS
and for 1.79% of the 4366 cases of isolated OPCAB proce-
dures in our study. Stenosis in the aorto-ostial location is ex-
tremely serious because a large myocardial territory is at
risk.23 The location of the ostial lesion may be a marker
for more extensive and advanced atherosclerosis. A numberery c January 2012
FIGURE 1. The Kaplan-Meier curves of freedom from major adverse
cardiac and cerebral events for the non–left main disease (Non-Mainstem
Disease) group, the nonostial left main stenosis (Non-Ostial-LMS) group,
and the ostial left main stenosis (Ostial-LMS) group. Cum Survival, Cumu-
lative survival.
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outcomes after OPCAB in the ostial LMS group. Off-
pump manipulation during OPCAB may be challenging,
and elastic stenosis may occur, which may lead to cardio-
vascular collapse.
One further question is whether, on the basis of our anal-
ysis, we should suggest that the ostial LMS lesion be treated
with an on-pump rather than an off-pump procedure. With-
out a comparative study between OPCAB and on-pump
CABG for ostial LMS, we do not believe that we can now
make a firm recommendation that these procedures should
all be done on pump, because their mortality and morbidity
might well remain high because of the nature of the disease
rather than the type of procedure performed. We have dem-
onstrated that this increased mortality was due to intra-
operative sudden hemodynamic instability during OPCAB
as the predominant problem, resulting in a potential chain
of events leading to increased mortality. Around 90% of pa-
tients in the ostial LMS group did well with OPCAB in an
experienced OPCAB center such as ours. It is therefore war-
ranted to recommend that a higher degree of intraoperative
surveillance for the early detection of problems and a lower
threshold for converting to an on-pump procedure, rather
than a blanket recommendation to do all these procedures
on pump. Moreover, to prevent emergency conversion for
the patient with a greater than 90% stenosis, prophylactic
implantation of an IABP may be a good measure.
The SYNTAX study,24 which compared PCI with drug-
eluting stents versus CABG, revealed that a SYNTAX score
threshold of 34 might identify patients who would benefit
most from surgical revascularization in terms of reducing
risk of death.25 Although the SYNTAX study providedThe Journal of Thoracic and Caa deep insight into LMS and 3-vessel disease, and it indeed
included aorto-ostial lesion in its subjects, it did not provide
interventional guidance for such specific lesions as ostial
LMS. Our study, by reviewing propensity score–matched
patients among the 3 groups, revealed that ostial LMS
does pose an additional risk relative to OPCAB procedure
in terms of early mortality and MACCEs. Most mortality
and MACCEs in the ostial LMS group in the first 30 days
after the procedure may be attributable to unstable hemody-
namics during the off-pump manipulation, which may stem
from the high elastic property of the stenosed ostium of the
left main coronary artery. These findings have further
expanded the findings of the SYNTAX study.
Because 4 of 5 early deaths in our series were after emer-
gency conversion to on-pump CABG (Table 3), our criteria
for conversion to on-pump CABG should be revised. The
hemodynamic response seen during lifting of the heart to
evaluate targets initially is very important. There are
enough data to suggest that mortality is significantly higher
when there is emergency conversion to on-pump CABG
during an OPCAB procedure. All the patients who have
a poor response to initial lifting should have elective conver-
sion to on-pump CABG. If this had been done, the mortality
might have been lessened.
In our series, the rate of conversion to cardiopulmonary
bypass in the ostial LMS group (10.26%) was significantly
higher than in the non–left main disease group (2.14%,
c2 ¼ 9.66, P ¼ .06) and the nonostial LMS group (1.92%,
c2¼ 8.06, P¼ .04). Prophylactic IABP placement can dra-
matically reduce the instability seen in critical patients and
allow a safer OPCAB procedure, but the percentage of
patients receiving preoperative IABP support was similar
across the 3 groups (Table 1). That may be another reason
for the higher incidence of emergency conversion to on-
pump CABG during an OPCAB procedure. After checking
these data, our surgical strategies for ostial LMS was re-
vised, in that we have adopted prophylactic IABP placement
for all patients with ostial LMS, especially for patients with
stenosis greater than 90%. Because conversion was signifi-
cantly frequent among patients with ostial LMS, adequate
preparation for pump application is necessary. We expect
that this change in the management protocol will decrease
the mortality among patients with ostial LMS.
Study Limitations
This study is a retrospective analysis, and some con-
founding factors may have hidden any clear association be-
tween the early and late prognoses of OPCAB and the
pathology of LMS. Although we used propensity score
matching to balance the 3 nonequivalent groups and reduce
any bias for a specific revascularization procedure, prospec-
tive, randomized, comparative trials are needed to confirm
the findings of this study. In addition, for this special entity
of ostial LMS, the relative efficacy of the off-pump CABGrdiovascular Surgery c Volume 143, Number 1 109
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Dprocedure versus the on-pump CABG is yet to be deter-
mined through further investigation, especially through ran-
domized, comparative trial. The long-term effects of ostial
LMS on OPCAB results still need to be defined further.
CONCLUSIONS
Nonostial LMS does not pose additional early risk after
OPCAB, but ostial LMS does, and this difference may
stem from the unstable hemodynamic situation during OP-
CAB. Therefore more caution and attention must be paid to
ostial LMS during OPCAB.We suggest that OPCAB proce-
dures for patients with ostial LMS should proceed with
a higher degree of intraoperative surveillance for the early
detection of problems and a lower threshold for converting
to on-pump CABG. IABP support may improve the out-
comes of OPCAB for ostial LMS, and because conversion
was significantly frequent in patients with ostial LMS, ade-
quate preparation for pump application is necessary.References
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